Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

Daniel A. Hamstra, MD, PhD
Published: Monday, Jan 11, 2016



Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing different lengths of radiation treatments for patients with prostate cancer.

The RTOG 0145 study compared an 8-week to 5.5-week regimen of radiation therapy in more than 1000 patients with prostate cancer, Hamstra explains. Outcomes were found to be identical regarding tumor recurrence and short- and long-term side effects, with a small increase in gastrointestinal-related effects in the longer regimen.

In the CHIP trial, more than 3000 patients from the United Kingdom were randomized to receive either an 8-week regimen, 19 treatments, or 20 treatments. In the 20-treatment arm, outcomes were reported to be similar in comparison to the 8-week regimen arm.

<<< View more from the 2016 GU Cancer Symposium



Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing different lengths of radiation treatments for patients with prostate cancer.

The RTOG 0145 study compared an 8-week to 5.5-week regimen of radiation therapy in more than 1000 patients with prostate cancer, Hamstra explains. Outcomes were found to be identical regarding tumor recurrence and short- and long-term side effects, with a small increase in gastrointestinal-related effects in the longer regimen.

In the CHIP trial, more than 3000 patients from the United Kingdom were randomized to receive either an 8-week regimen, 19 treatments, or 20 treatments. In the 20-treatment arm, outcomes were reported to be similar in comparison to the 8-week regimen arm.

<<< View more from the 2016 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x